1921
Volume 76, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

response to chloroquine, monodesethylamodiaquine, mefloquine, lumefantrine, and dihydroartemisinin was assessed by the radioisotopic microtest in Yaoundé, Cameroon, during 2000–2004 and compared with our previous data obtained during 1996–1999. Based on the cut-off value of 100 nmol/L, 36.3% of isolates were chloroquine-susceptible ( = 175; geometric mean IC, 40.3 nmol/L) and 63.7% were chloroquine-resistant ( = 307; geometric mean IC, 211 nmol/L). There was no significant difference ( > 0.05) in the mean ICs from 1996 to 2004, but a significant linear trend ( < 0.05) toward an increased proportion of chloroquine-resistant isolates was observed from 1996 (49%) to 2004 (69%). All chloroquine-susceptible isolates and most chloroquine-resistant isolates were susceptible to monodesethylamodiaquine (i.e., IC < 60 nmol/L). Despite the positive correlation between chloroquine and monodesethylamodiaquine ( = 0.739, < 0.05), the ICs for monodesethylamodiaquine remained stable during 1997–2004, with no increase in the proportion of monodesethylamodiaquine-resistant isolates. Mefloquine, lumefantrine, and dihydroartemisinin were equally active against the chloroquine-susceptible and chloroquine-resistant parasites. The responses to these three drugs were positively correlated, and a significant decrease ( < 0.05) in the mean ICs was observed during the study period compared with our earlier data in 1997–1999, probably because of their inverse relationship with chloroquine response. The results were in general agreement with the response to chloroquine and amodiaquine. drug susceptibility assay is a useful, complementary laboratory tool for determining the trend of response to drugs for which there is still no established molecular marker and may serve as an early warning system for emerging drug resistance.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2007.76.20
2007-01-01
2017-09-21
Loading full text...

Full text loading...

/deliver/fulltext/14761645/76/1/0760020.html?itemId=/content/journals/10.4269/ajtmh.2007.76.20&mimeType=html&fmt=ahah

References

  1. Basco LK, Foumane Ngane V, Ndounga M, Same-Ekobo A, Youmba JC, Okalla Abodo RT, Soula G, 2006. Molecular epidemiology of malaria in Cameroon. XXI. Baseline therapeutic efficacy of chloroquine, amodiaquine, and sulfadoxine-pyrimethamine monotherapies in children before national drug policy change. Am J Trop Med Hyg 75 : 388–395.
  2. World Health Organization, 2005. Susceptibility of Plasmodium falciparum to Antimalarial Drugs. Report on Global Monitoring 1996–2004. Geneva: World Health Organization.
  3. Mount DL, Nahlen BL, Patchen LC, Churchill FC, 1989. Adaptations of the Saker-Solomons test: Simple, reliable colorimetric field assays for chloroquine and its metabolites in urine. Bull World Health Organ 67 : 295–300.
  4. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD, 1979. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother 16 : 710–718.
  5. Ringwald P, Bickii J, Basco LK, 1998. Amodiaquine as the first-line treatment of malaria in Yaoundé, Cameroon: presumptive evidence from activity in vitro and cross-resistance patterns. Trans R Soc Trop Med Hyg 92 : 212–213.
  6. Basco LK, Ndounga M, Keundjian A, Ringwald P, 2002. Molecular epidemiology of malaria in Cameroon. IX. Characteristics of recrudescent and persistent Plasmodium falciparum infections after chloroquine or amodiaquine treatment in children. Am J Trop Med Hyg 66 : 117–123.
  7. Basco LK, Bickii J, Ringwald P, 1998. In vitro activity of lumefantrine (benflumetol) against clinical isolates of Plasmodium falciparum in Yaoundé, Cameroon. Antimicrob Agents Chemother 42 : 2347–2351.
  8. Ringwald P, Eboumbou ECM, Bickii J, Basco LK, 1999. In vitro activity of pyronaridine, alone and in combination with other antimalarial drugs, against Plasmodium falciparum. Antimicrob Agents Chemother 43 : 1525–1527.
  9. Ringwald P, Bickii J, Basco LK, 1999. In vitro activity of dihydroartemisinin against clinical isolates of Plasmodium falciparum in Yaoundé, Cameroon. Am J Trop Med Hyg 61 : 187–192.
  10. Ringwald P, Basco LK, 1999. Comparison of in vivo and in vitro tests of resistance in patients treated with chloroquine in Yaoundé, Cameroon. Bull World Health Organ 77 : 34–43.
  11. Ringwald P, Same Ekobo A, Keundjian A, Kedy Mangamba D, Basco LK, 2000. Chimiorésistance de P. falciparum en milieu urbain à Yaoundé, Cameroun. Part I: Surveillance in vitro et in vivo de la résistance de Plasmodium falciparum à la chloroquine entre 1994 et 1999 à Yaoundé, Cameroun. Trop Med Int Health 5 : 612–619.
  12. Ringwald P, Keundjian A, Same-Ekobo A, Basco LK, 2000. Chimiorésistance de P. falciparum en milieu urbain à Yaoundé, Cameroun. Part 2: Evaluation de l’efficacité de l’amodiaquine et de l’association sulfadoxine-pyriméthamine pour le traitement de l’accès palustre simple à Plasmodium falciparum à Yaoundé, Cameroun. Trop Med Int Health 5 : 620–627.
  13. Basco LK, Ringwald P, 2003. In vitro activities of piperaquine and other 4-aminoquinolines against clinical isolates of Plasmodium falciparum in Cameroon. Antimicrob Agents Chemother 47 : 1391–1394.
  14. Basco LK, 2003. Molecular epidemiology of malaria in Cameroon. XVI. Longitudinal surveillance of in vitro pyrimethamine resistance. Am J Trop Med Hyg 69 : 174–178.
  15. Basco LK, 2004. Molecular epidemiology of malaria in Cameroon. XIX. Quality of antimalarial drugs used for self-medication. Am J Trop Med Hyg 70 : 245–250.
  16. Basco LK, 2002. Molecular epidemiology of malaria in Cameroon. XIII. Analysis of pfcrt mutations and in vitro chloroquine resistance. Am J Trop Med Hyg 67 : 388–391.
  17. Basco LK, Same-Ekobo A, Foumane Ngane V, Ndounga M, Metoh T, Ringwald P, Soula G, 2002. Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine, and sulfadoxine-pyrimethamine-amodiaquine combination for the treatment of uncomplicated Plasmodium falciparum malaria in young children in Cameroon. Bull World Health Organ 80 : 538–545.
  18. Olliaro P, Nevill C, Le Bras J, Ringwald P, Mussano P, Garner P, Brasseur P, 1996. Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet 348 : 1196–1201.
  19. Brasseur P, Guiguemde R, Diallo S, Guiyedi V, Kombila A, Ringwald P, Olliaro P, 1999. Amodiaquine remains effective for treating uncomplicated malaria in West and Central Africa. Tran R Soc Trop Med Hyg 93 : 645–650.
  20. Hall AP, Segal HE, Pearlman EJ, Phintuyothin P, Kosakal S, 1975. Amodiaquine resistant falciparum malaria in Thailand. Am J Trop Med Hyg 24 : 575–580.
  21. Pinichpongse S, Doberstyn EB, Cullen JR, Yisunri L, Thongsombun Y, Thimarsan K, 1982. An evaluation of five regimens for the outpatient therapy of falciparum malaria in Thailand 1980–81. Bull World Health Organ 60 : 907–912.
  22. Khaliq AA, Fox E, Sarwar M, Strickland GT, 1987. Amodiaquine fails to cure chloroquine-resistant Plasmodium falciparum in the Punjab. Trans R Soc Trop Med Hyg 81 : 157–159.
  23. Le Bras J, Simon F, Ramanamirija JA, Calmel MB, Hatin I, Deloron P, Porte J, Marchais H, Clausse JL, Biaud JM, Sarrouy J, Guiguemde TR, Carme B, Charmot G, Coulaud JP, Coulanges P, 1987. Sensibilité de Plasmodium falciparum aux quinoléines et stratégies thérapeutiques: comparaison de la situation en Afrique et à Madagascar entre 1983 et 1986. Bull Soc Pathol Exot 80 : 477–489.
  24. Childs GE, Boudreau EF, Milhous WK, Wimonwattrattee T, Pooyindee N, Pang L, Davidson DE, 1989. A comparison of the in vitro activities of amodiaquine and desethylamodiaquine against isolates of Plasmodium falciparum. Am J Trop Med Hyg 40 : 7–11.
  25. Basco LK, Le Bras J, 1993. In vitro activities of monodesethylamodiaquine and amopyroquine against African isolates and clones of Plasmodium falciparum. Am J Trop Med Hyg 48 : 120–125.
  26. Adjuik M, Agnamey P, Babiker A, Borrmann S, Brasseur P, Cisse M, Cobelens F, Diallo S, Faucher JF, Garner P, Gikunda S, Kremsner PG, Krishna S, Lell B, Loolpapit M, Matsiegui PB, Missinou MA, Mwanza J, Ntoumi F, Olliaro P, Osimbo P, Rezbach P, Some E, Taylor WR, 2002. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet 359 : 1365–1372.
  27. Dorsey G, Njama D, Kamya MR, Cattamanchi A, Kyabayinze D, Staedke SG, Gasasira A, Rosenthal PJ, 2002. Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet 360 : 2031–2038.
  28. Bohannon J, 2006. Profile: Arata Kochi. Fighting words from WHO’s new malaria chief. Science 311 : 599.
  29. Doury JC, Ringwald P, Guelain J, Le Bras J, 1992. Susceptibility of African isolates of Plasmodium falciparum to artemisinin (qinghaosu). Trop Med Parasitol 43 : 197–198.
  30. Basco LK, Le Bras J, 1993. In vitro activity of artemisinin derivatives against African isolates and clones of Plasmodium falciparum. Am J Trop Med Hyg 49 : 301–307.
  31. Bustos MDG, Gay F, Diquet B, 1994. In vitro tests on Philippine isolates of Plasmodium falciparum against four standard antimalarials and four qinghaosu derivatives. Bull World Health Organ 72 : 729–735.
  32. Pradines B, Rogier C, Fusai T, Tall A, Trape JF, Doury JC, 1998. In vitro activity of artemether against African isolates (Senegal) of Plasmodium falciparum in comparison with standard antimalarial drugs. Am J Trop Med Hyg 58 : 354–357.
  33. Tanariya P, Tippawangkoso P, Karbwang J, Na-Bangchang K, Wernsdorfer WH, 2000. In vitro sensitivity of Plasmodium falciparum and clinical response to lumefantrine (benflumetol) and artemether. Br J Clin Pharmacol 49 : 437–444.
  34. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF, 2000. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 403 : 906–909.
  35. Duraisingh MT, Roper C, Walliker D, Warhurst DC, 2000. Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdr1 gene of Plasmodium falciparum. Mol Microbiol 36 : 955–961.
  36. Oduola AMJ, Milhous WK, Salako LA, Walker O, Desjardins RE, 1987. Reduced in vitro susceptibility to mefloquine in West African isolates of Plasmodium falciparum. Lancet 2 : 1304–1305.
  37. Brossi A, Venugopalan B, Dominguez-Gerpe L, Yeh HJC, Flippen-Anderson JL, Buchs P, Luo XD, Milhous W, Peters W, 1988. Arteether, a new antimalarial drug: synthesis and anti-malarial properties. J Med Chem 31 : 645–650.
  38. Simon F, Le Bras J, Gaudebout C, Girard PM, 1988. Reduced sensitivity of Plasmodium falciparum to mefloquine in West Africa. Lancet 1 : 467–468.
  39. Basco LK, Ringwald P, 2001. Molecular epidemiology of malaria in Yaounde, Cameroon. VIII. Multiple Plasmodium falciparum infections in symptomatic patients. Am J Trop Med Hyg 65 : 798–803.
  40. Basco LK, Tahar R, Escalante A, 2004. Molecular epidemiology of malaria in Cameroon. XVIII. Polymorphisms of the Plasmodium falciparum merozoite surface antigen-2 gene in isolates from symptomatic patients. Am J Trop Med Hyg 70 : 238–244.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2007.76.20
Loading
/content/journals/10.4269/ajtmh.2007.76.20
Loading

Data & Media loading...

  • Received : 23 Mar 2006
  • Accepted : 04 Sep 2006

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error